Homology Competitors

Delisted . USA . 
Stock . Homology Medicines
FIXXDelisted Stock  USD 1.09  0.06  5.83%   
Homology Medicines competes with Passage Bio, Stoke Therapeutics, Adaptimmune Therapeutics, Black Diamond, and 4D Molecular; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Homology Medicines competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Homology Medicines to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Homology Medicines competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Homology Medicines' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.091.091.09
Details
Intrinsic
Valuation
LowRealHigh
0.880.881.20
Details

Homology Medicines Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Homology Medicines and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Homology and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Homology Medicines does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BDTX
+ 0.96
ADAP
FDMT
+ 0.94
BDTX
FDMT
+ 0.89
ADAP
BDTX
+ 0.86
PASG
ADAP
+ 0.82
PASG
FDMT
+ 0.8
PASG
  
High negative correlations   
FDMT
- 0.71
TCRR
BDTX
- 0.7
TCRR
ADAP
- 0.66
TCRR
HARP
- 0.59
ADAP
HARP
- 0.55
BDTX
FDMT
- 0.5
HARP

Risk-Adjusted Indicators

There is a big difference between Homology Stock performing well and Homology Medicines Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Homology Medicines' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Homology Medicines Competitive Analysis

The better you understand Homology Medicines competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Homology Medicines' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Homology Medicines' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
FIXX PASG STOK BCEL TCRR ADAP BDTX HARP FDMT
 5.83 
 1.09 
Homology
 21.57 
 0.62 
Passage
 3.06 
 11.78 
Stoke
 1.89 
 1.04 
Atreca
 0.00 
 1.48 
Tcr2
 6.06 
 0.70 
Adaptimmune
 1.18 
 2.51 
Black
 0.00 
 0.85 
Harpoon
 2.18 
 7.62 
FDMT
Market Volatility
(90 Days Market Risk)
Very steady
Dangerous
Somewhat reliable
Very steady
Very steady
Dangerous
Relatively risky
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
High
Low
Dangerous
Dangerous
Quite High
Quite High
Dangerous
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Buy
Strong Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Sell
Not Rated
Not Rated
Strong Sell
Strong Sell
Not Rated
Strong Sell
Current Ratio
8.44
9.23
10.46
8.14
5.02
4.0
8.55
1.62
17.2
Net Asset
306.12 M
150.54 M
228.34 M
155.03 M
208.24 M
282.62 M
158.57 M
73.73 M
339.89 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
-0.51
N/A
-0.82
N/A
EBITDA
(91.52 M)
(98.34 M)
(112.3 M)
(76.42 M)
(89.62 M)
(128.2 M)
(86.02 M)
(35.45 M)
(107.12 M)
Operating Margin
-78.85
N/A
-6.13
N/A
N/A
0.54
N/A
-2.73
N/A
Current Valuation
(27 M)
(27.82 M)
368.51 M
(17.08 M)
(73.69 M)
57.7 M
54.04 M
475.25 M
(116.94 M)
Price To Book
0.0414
0.43
2.61
0.28
0.22
2.12
1.48
108.42
0.65
Retained Earnings
(542.1 M)
(594.47 M)
(401.85 M)
(456.92 M)
(501.34 M)
(1.02 B)
(417.43 M)
(352.52 M)
(415.33 M)
Current Asset
48.82 M
144.91 M
N/A
60.02 M
N/A
199.54 M
123.51 M
119.62 M
N/A
Beta
-0.11
1.2
0.95
1.17
1.93
2.25
2.52
2.1
2.8
Number Of Employees
7
58
110
90
58
449
54
53
147
Shares Outstanding
3.23 M
61.77 M
52.97 M
38.41 M
39.26 M
255.88 M
56.59 M
21.4 M
46.23 M
Cash Flow From Operations
(96.23 M)
(78.26 M)
(81.07 M)
(65.08 M)
(101.46 M)
(140.88 M)
(66.72 M)
(69.38 M)
(75.79 M)
Total Debt
1.32 M
26.29 M
6.83 M
63.88 M
58.23 M
25.23 M
25.3 M
16.01 M
14.67 M
Return On Equity
-0.9
-0.64
-0.52
-1.83
-0.91
-0.65
-0.63
-2.84
-0.24
Z Score
N/A
N/A
N/A
-5.25
-3.54
N/A
N/A
10.72
N/A
Return On Asset
-0.36
-0.34
-0.28
-0.51
-0.35
-0.16
-0.33
-0.36
-0.17
Number Of Shares Shorted
338.72 K
1.64 M
6.7 M
272.73 K
360.89 K
5.35 M
6.33 M
1.16 M
8.18 M
Book Value Per Share
22.65
2.03
4.38
0.27
2.58
0.17
1.72
1.11
7.15
Current Liabilities
8.27 M
3.09 M
N/A
3.56 M
N/A
22.66 M
4.43 M
18.4 M
N/A
Total Asset
306.12 M
150.54 M
228.34 M
155.03 M
208.24 M
282.62 M
158.57 M
73.73 M
339.89 M
Debt To Equity
0.14
0.11
0.026
0.57
0.29
0.2
0.19
0.43
0.062
Short Ratio
0.62
6.61
13.69
0.16
1.29
4.71
7.7
0.37
9.89
Target Price
1.5
7.67
22.29
5.5
6.43
2.43
14.5
23.67
45.64
Shares Owned By Institutions
46.75
59.68
95.51
24.54
54.32
60.26
98.99
82.85
96.09
Market Capitalization
3.02 M
31.19 M
605.41 M
3.02 M
58.11 M
169.29 M
143.73 M
492.35 M
360.11 M
Price To Earning
-10.0
N/A
N/A
-3.53
N/A
-7.73
N/A
-5.61
N/A
Price To Earnings To Growth
21.38
N/A
0.27
N/A
N/A
0.11
N/A
N/A
-0.07
Price To Sales
2.61
N/A
36.16
N/A
N/A
1.2
N/A
13.19
21183.16
Net Income
(112.96 M)
(102.06 M)
(104.7 M)
(97.76 M)
(151.82 M)
(113.87 M)
(82.44 M)
(30.5 M)
(100.84 M)
Earnings Per Share
-35.1
-1.17
-2.08
-2.5
-4.2
-0.17
-1.33
-8.62
-2.85
Shares Owned By Insiders
9.2
0.49
4.49
2.73
1.5
0.37
2.26
0.34
3.91
Revenue
1.16 M
N/A
8.78 M
N/A
N/A
60.28 M
N/A
37.34 M
20.72 M
Working Capital
72.34 M
101.62 M
184.52 M
61.73 M
113.56 M
134.76 M
114.39 M
2.29 M
277.64 M
Cash And Equivalents
201.07 M
239.25 M
275.63 M
101.73 M
175.99 M
199.67 M
160.89 M
90.15 M
241.09 M
Cash Per Share
3.5
4.39
6.99
2.64
4.55
1.22
4.43
2.72
7.45
Gross Profit
(95.14 M)
N/A
12.4 M
N/A
N/A
(100.58 M)
N/A
(49.48 M)
(77.12 M)
Day Typical Price
1.07
0.59
11.84
1.06
1.48
0.69
2.55
0.84
7.79
Accumulation Distribution
0.0727
315594.0
25813.13
0.0804
N/A
101043.0
17164.48
0.0465
79509.73
Market Facilitation Index
0.08
N/A
0.0
0.09
N/A
N/A
N/A
0.04
0.0
Daily Balance Of Power
0.75
0.5
0.4795
(0.22)
0.0
0.8
(0.23)
N/A
(0.24)
Period Momentum Indicator
0.06
0.11
0.35
(0.02)
N/A
0.04
(0.03)
N/A
(0.17)
Rate Of Daily Change
1.06
1.22
1.03
0.98
1.0
1.06
0.99
1.0
0.98
Day Median Price
1.06
0.58
11.88
1.08
1.48
0.69
2.58
0.84
7.88
Price Action Indicator
0.06
0.095
0.08
(0.04)
N/A
0.035
(0.08)
0.01
(0.34)
Coefficient Of Variation
2408.52
(1,637)
(1,702)
2475.92
1404.52
(630.84)
(363.64)
846.77
(490.27)
Mean Deviation
2.82
4.69
2.63
3.9
3.16
3.18
3.64
3.55
2.79
Jensen Alpha
0.1365
(0.62)
(0.38)
0.2078
0.4618
(0.93)
(1.52)
0.5434
(0.82)
Total Risk Alpha
(0.44)
(1.28)
(0.79)
(0.61)
(0.48)
(1.50)
(1.94)
(0.20)
(1.51)
Sortino Ratio
0.0056
N/A
N/A
0.0133
0.0653
N/A
N/A
0.1089
N/A
Downside Variance
16.92
N/A
N/A
33.68
15.4
N/A
N/A
15.83
N/A
Standard Deviation
3.71
5.79
3.63
5.15
5.44
4.72
4.45
4.78
4.14
Kurtosis
0.7375
(0.53)
2.37
0.6864
21.78
7.8
(0.24)
1.18
6.54
Potential Upside
5.77
9.33
4.68
7.53
5.77
5.56
5.56
9.59
5.15
Treynor Ratio
2.33
(0.17)
(0.17)
(2.50)
(0.54)
(0.52)
(0.52)
6.28
2.59
Maximum Drawdown
19.43
25.5
21.35
23.8
43.6
33.29
19.51
22.48
25.71
Variance
13.76
33.57
13.18
26.57
29.56
22.27
19.82
22.82
17.16
Market Risk Adjusted Performance
2.34
(0.16)
(0.16)
(2.49)
(0.53)
(0.51)
(0.51)
6.29
2.6
Risk Adjusted Performance
0.0398
(0.04)
(0.04)
0.0395
0.0632
(0.11)
(0.20)
0.099
(0.15)
Skewness
(0.24)
(0.14)
(0.74)
(0.55)
3.52
(1.13)
(0.11)
0.8356
(1.28)
Semi Deviation
3.52
N/A
N/A
5.0
3.26
N/A
N/A
3.28
N/A
Information Ratio
0.0063
(0.08)
(0.09)
0.015
0.0471
(0.19)
(0.30)
0.0907
(0.24)
Value At Risk
(5.61)
(9.88)
(6.99)
(9.65)
(6.25)
(6.00)
(8.30)
(6.25)
(5.78)
Expected Short fall
(3.25)
N/A
N/A
(4.64)
(4.40)
N/A
N/A
(5.07)
N/A
Downside Deviation
4.11
N/A
N/A
5.8
3.92
N/A
N/A
3.98
N/A
Semi Variance
12.41
N/A
N/A
25.05
10.66
N/A
N/A
10.79
N/A

Homology Medicines Competition Performance Charts

Five steps to successful analysis of Homology Medicines Competition

Homology Medicines' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Homology Medicines in relation to its competition. Homology Medicines' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Homology Medicines in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Homology Medicines' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Homology Medicines, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Homology Medicines position

In addition to having Homology Medicines in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small & Mid Caps ETFs Thematic Idea Now

Small & Mid Caps ETFs
Small & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Consideration for investing in Homology Stock

If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY